Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucoregulatory Effects of Risperidone and Olanzapine in Schizophrenia
NCT00236379Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of risperidone in schizophrenia and schizoaffective disorder (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change in Disposition Index derived from the Frequently Sampled Intravenous Glucose Tolerance Test at 6 months. Status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00236379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236379.